Autolus Therapeutics (AUTL) announced that Autolus will assess the feasibility of Cellares’ Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in Stevenage, UK. Autolus commercializes AUCATZYL, an autologous CD19 CAR T cell therapy approved in the United States, UK, and Europe for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Obe-cel is also being studied in ongoing clinical trials to potentially expand its use in pediatric r/r B-ALL, and autoimmune diseases, such as lupus and multiple sclerosis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Needham ups Autolus target, names top pick for 2026
- Autolus Therapeutics presents data from CATULUS Phase 1 trial of obe-cel
- Autolus Therapeutics Appoints Ryan Richardson to Board
- Autolus Therapeutics appoints Ryan Richardson to board of directors